Tiziana Life Sciences Expands Phase 2 Trial for Multiple Sclerosis Treatment

Tiziana Life Sciences ( (TLSA) ) has issued an announcement.

On April 2, 2025, Tiziana Life Sciences announced the commencement of dosing at Johns Hopkins University for its Phase 2 trial of intranasal foralumab, aimed at treating non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This trial, which also includes Brigham and Women’s Hospital and Yale Medical Center, seeks to evaluate the safety and efficacy of foralumab, a promising treatment for na-SPMS, a condition with limited current treatment options. The trial’s expansion to a third site underscores Tiziana’s commitment to advancing innovative treatments for neurodegenerative diseases, with the blinded portion expected to conclude by the end of 2025, followed by an open-label extension period.

More about Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using transformational drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody that has shown a favorable safety profile and clinical response. The company’s innovative nasal delivery approach aims to improve efficacy, safety, and tolerability compared to traditional intravenous delivery methods.

YTD Price Performance: 55.88%

Average Trading Volume: 998,800

Technical Sentiment Signal: Sell

Current Market Cap: $119.5M

See more insights into TLSA stock on TipRanks’ Stock Analysis page.